FDA Orders Unapproved Oxycodone Drugs Halted

Its notice in the Federal Register affects companies that manufacture and distribute unapproved single-ingredient, immediate-release oxycodone drug products in oral dosage forms, including tablets, capsules, and oral solutions.

The U.S. Food and Drug Administration has published a notice ordering companies to stop manufacturing and distributing some unapproved drugs that contain oxycodone. The agency said this step is part of its Unapproved Drugs Initiative to remove unapproved new drugs from the market.

The affected drugs -- single-ingredient, immediate-release oxycodone drug products in oral dosage forms, including tablets, capsules, and oral solutions -– haven't been evaluated by FDA for safety, effectiveness, manufacturing quality, or appropriate labeling. Oxycodone is listed under Schedule II of the Controlled Substances Act with an abuse liability similar to other opioid agonists.

The notice says FDA is aware of unapproved 5 mg capsules and unapproved oral solutions in 5 mg/5 mL and 20 mg/mL strengths. It also is aware of two adverse events cited in the notice: a 21-month-old patient prescribed oxycodone at a strength of 1 mg/mL but instead given one at 20 mg/mL who suffered respiratory failure but was successfully resuscitated, and an 18-year-old patient whose prescription was to take one 5 mg teaspoon every four hours but was given a 20 mg/mL solution. This second patient went into a coma with organ failure and was placed in intensive care, and at the time of the report to FDA "was able to speak but only with a limited vocabulary," according to the notice.

"It's a high public health priority for FDA to remove these unapproved products from the market to minimize consumer exposure to drugs that may be unsafe, ineffective, and of poor quality," said Ilisa Bernstein, acting director of the Office of Compliance in FDA's Center for Drug Evaluation and Research. "Since FDA-approved versions of these oral dosage forms are available by prescription, there should be no negative impact on consumers as a result of this action and no disruptions to the drug supply."

Companies are expected to stop making the products within 45 days and stop shipping them within 90 days. Affected products were introduced onto the market before Sept. 19, 2011, were listed in FDA's Drug Registration and Listing System before July 6, 2012, and were being commercially used or sold before July 6, 2012.

Download Center

HTML - No Current Item Deck
  • Free Safety Management Software Demo

    IndustrySafe Safety Management Software helps organizations to improve safety by providing a comprehensive toolset of software modules to help businesses identify trouble spots; reduce claims, lost days, OSHA fines; and more.

  • The Top 5 Safety and Technology Trends to Watch in 2019

    Get the latest on trends you can expect to hear more about in 2019, including continued growth of mobile safety applications, wearable technology, and smart PPE; autonomous vehicles; pending OSHA recordkeeping rulemaking; and increased adoption of international safety standard, ISO 45001.

  • Get the Ultimate Guide to OSHA Recordkeeping

    OSHA’s Form 300A posting deadline is February 1! Are you prepared? To help answer your key recordkeeping questions, IndustrySafe put together this guide with critical compliance information.

  • Safety Training 101

    When it comes to safety training, no matter the industry, there are always questions regarding requirements and certifications. We’ve put together a guide on key safety training topics, requirements for certifications, and answers to common training questions.

  • Conduct EHS Inspections and Audits

    Record and manage your organization’s inspection data with IndustrySafe’s Inspections module. IndustrySafe’s pre-built forms and checklists may be used as is, or can be customized to better suit the needs of your organization.

  • Industry Safe

OH&S Digital Edition

  • OHS Magazine Digital Edition - January 2019

    January 2019

    Featuring:

    • PREVENTING ERRORS
      Production vs. Safety 
    • EMERGENCY SHOWERS & EYEWASH
      Meeting the Requirements for Emergency Equipment
    • CONSTRUCTION SAFETY
      The State of Contractor Safety
    • FOOT PROTECTION
      The Three Keys to Effective Chemical Management
    View This Issue